Pfizer Reports Easing of Major Challenges as Pipeline and Obesity Initiatives Gain Momentum
Pfizer Inc. (NYSE:PFE) has indicated that major challenges, including tariff concerns and pricing pressures from the most-favored-nation policy, are easing. CEO Albert Bourla highlighted at a Morgan Stanley conference that Pfizer outperformed revenue expectations in nine of its last ten earnings reports and exceeded EPS forecasts consistently over 2024–2026. The company has reduced costs by $7.2 billion over three years to offset patent expirations, while new products from business development now contribute about $13 billion annually at a growth rate exceeding 20%. Pfizer is shifting focus toward its pipeline and obesity initiatives as key drivers of future revenue. Late-stage results for the prostate-cancer drug mevrometostat are expected by year-end, while Metsera’s obesity portfolio includes weekly/monthly GLP-1 treatments, an amylin combination therapy, and an oral candidate. Bourla also noted that investor attention is moving away from past issues like declining demand post-pandemic toward upcoming clinical catalysts in 2027. Regarding policy developments, Bourla expressed cautious optimism about bipartisan efforts such as pharmacy benefit manager reform but remained skeptical of broader resolutions for the controversial 340B drug-pricing program. A pilot involving Pfizer’s ELIQUIS and IBRANCE is set to begin in January 2027.
Topics: earnings performance M&A strategy obesity treatments pharmaceuticals pipeline developments